Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2
- 1 June 1992
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 3 (6), 475-480
- https://doi.org/10.1093/oxfordjournals.annonc.a058239
Abstract
A database of 327 patients with advanced Renal Cell Carcinoma (RCC) has been analyzed in order to identify potential baseline prognostic factors predicting for survival, following recombinant Interleukin-2 treatment (rIL-2). All patients received a continuous infusion (CIV). Eligibility criteria were uniform across studies, and included patients with an ambulatory performance status (PS), measurable disease, no CNS metastases, and no major organ compromise. Multivariate analyses identified baseline PS (ECOG 0 vs. I), time from diagnosis to treatment (DTI >24 months vs. ⩽24 months), and the number of metastatic sites (1 vs. ⩾2, where lung, bone and other sites are considered as separate sites) as important predictors for survival. Patients can be classified into 4 subgroups, which are a function of the number of risk factors present. Median survival for each subgroup is 28, 17, 10 and 5 months, respectively. The model was validated in an independent cohort of 125 patients with RCC treated with subcutaneous (s/c) rIL-2, and predicted for survival accurately. By determining in which risk group category patients may fall, treating physicians may be better equipped to decide on patient management. The model may also be of value in order to stratify patients in randomized clinical trials.This publication has 12 references indexed in Scilit:
- Interleukin-2: Further Progress Through Greater UnderstandingJNCI Journal of the National Cancer Institute, 1990
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Prognosis in primary biliary cirrhosis: Model for decision makingHepatology, 1989
- Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignanciesCancer Treatment Reviews, 1989
- Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patientsCancer Treatment Reviews, 1989
- Prognostic factors of adult metastatic renal carcinoma: A multivariate analysisSeminars in Surgical Oncology, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Prognostic Factors in Metastatic Renal CarcinomaJournal of Urology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958